<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1570">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02011100</url>
  </required_header>
  <id_info>
    <org_study_id>CarnoDMCVD</org_study_id>
    <nct_id>NCT02011100</nct_id>
  </id_info>
  <brief_title>Effect of Carnosine on Diabetes and Cardiovascular Risk Factors</brief_title>
  <acronym>Carnorisk</acronym>
  <official_title>Randomised Placebo Controlled Study of the Effect of Carnosine Diabetes and Cardiovascular Risk Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jozef Ukropec</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Slovak Academy of Sciences</source>
  <oversight_info>
    <authority>Slovak Republic: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carnosine is a naturally occurring compound with a potential health benefits. In animal
      studies, carnosine supplementation reduces manifestation of chronic civilization diseases,
      regulates subclinical inflammation, protein glycation and lipid &amp; glucose metabolism. Our
      preliminary data showed the relationship between insulin resistance and carnosine content in
      human skeletal muscle. Based on these unique results we plan to perform intervention study
      aimed at identifying effects of carnosine on insulin sensitivity and secretion, which might
      reduce the development of T2D in obese. Similar metabolic effects of vitamin D3 were
      associated with expression of specific miRNAs. Circulating miRNAs related to carnosine
      action are unknown. The putative positive effects of carnosine on insulin sensitivity and
      secretion in obese patients might have a tremendous impact in prevention of type 2 diabetes.
      Identification of miRNAs associated with carnosine action could provide predictors of
      successful therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>oxidative stress</measure>
    <time_frame>within one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>AGEs and lipid peroxidation products</description>
  </primary_outcome>
  <primary_outcome>
    <measure>chronic systemic inflammation</measure>
    <time_frame>one year</time_frame>
    <description>circulating hsCRP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>level of glucose intolerance</measure>
    <time_frame>within 10 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>detected by the oral glucose tolerance test. expressed as 2h glucose, area under the glycemic curve, QUICKI index, HOMA-IR</description>
  </secondary_outcome>
  <other_outcome>
    <measure>muscle carnosine content</measure>
    <time_frame>within 9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>assessed by 1H-MRS  of muscle in vivo (7T Magnet, Siemens, Germany) it will be expressed relative to creatine signal.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Metabolic Diseases, Type 2 Diabetes, Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>CARNOSINE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 months oral carnosine administration in a dose of 2 gram per day, twice a day 1 gram dose (1-0-1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 months placebo intake - taken twice a day (1-0-1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Carnosine</intervention_name>
    <arm_group_label>CARNOSINE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI (28-38 kg.m-2);

          -  waist circumference &gt;94 cm;

          -  % body fat 30%

          -  fasting glycemia &lt; 7 mmol/l

        Exclusion Criteria:

          -  age &lt; 25 or &gt; 50 years,

          -  change in body weight &gt; 5 kg in last 12 months,

          -  obesity with BMI &gt; 38kg.m-2,

          -  previously or newly (oGTT) diagnosed type 2 diabetes,

          -  allergy, smoking, alcohol abuse, any pharmacotherapy including regular vitamin
             intake;

          -  cardiovascular, hematologic, respiratory, gastrointestinal, endocrine or oncologic
             diseases,

          -  kidney disease, acute inflammatory disease.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jozef Ukropec, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of experimental endocrinology SAS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara Ukropcova, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Medicine Comenius University &amp; Institute of Experimental Endocrinology SAS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Boris Krahulec, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital in Bratislava</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Ukropcova, MD, PhD</last_name>
    <phone>+421-2-5477-2800</phone>
    <phone_ext>254</phone_ext>
    <email>barbara.ukropcova@savba.sk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jozef Ukropec, PhD</last_name>
    <phone>+421-2-5477-2800</phone>
    <phone_ext>205</phone_ext>
    <email>jozef.ukropec@savba.sk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Experimental Endocrinology Slovak Academy of Sciences</name>
      <address>
        <city>Bratislava</city>
        <zip>83306</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Ukropcova, MD, PhD</last_name>
      <phone>+421-2-5477-2800</phone>
      <phone_ext>254</phone_ext>
      <email>barbara.ukropcova@savba.sk</email>
    </contact>
    <investigator>
      <last_name>Jozef Ukropec, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michaela Jakubova, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara Ukropcova, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univeristy Hospital in Bratislava</name>
      <address>
        <city>Bratislava</city>
        <zip>81369</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris Krahulec, MD, PhD</last_name>
      <email>boris.krahulec@sm.unb.sk</email>
    </contact>
    <investigator>
      <last_name>Boris Krahulec, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 12, 2013</lastchanged_date>
  <firstreceived_date>December 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Slovak Academy of Sciences</investigator_affiliation>
    <investigator_full_name>Jozef Ukropec</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
